Immunotherapy against several tumors including neuronal and brain tumors
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
1. A method of inducing a CD8+ cytotoxic T cell response in a HLA-A*02+ patient having glioblastoma overexpressing an EGFR polypeptide comprising the amino acid sequence of ALAVLSNYDA (SEQ ID NO: 9) and presenting at its surface a peptide consisting of the amino acid sequence of SEQ ID NO: 9 in the context of a complex with an MHC class I molecule, said method comprising administering to the patient an effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO: 9 or a peptide consisting of the amino acid sequence of SEQ ID NO: 9 in the form of a pharmaceutically acceptable salt.
2. A method of inducing a CD8+ cytotoxic T cell response in a HLA-A*02+ patient having glioblastoma overexpressing an EGFR polypeptide comprising the amino acid sequence of ALAVLSNYDA SEQ ID NO: 9 and presenting at its surface a peptide consisting of the amino acid sequence of SEQ ID NO: 9 in the context of a complex with an MHC class I molecule, said method comprising administering to the patient an effective amount of a fusion protein comprising a peptide consisting of the amino acid sequence of ALAVLSNYDA (SEQ ID NO: 9), wherein the peptide is adjoined at the N-terminus and/or the C-terminus by the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain, Ii.
3. The method of claim 1 , wherein the peptide is acylated.
4. The method of claim 1 , wherein the peptide is pegylated.
5. The method of claim 1 , wherein the pharmaceutical pharmaceutically acceptable salt is a chloride salt or acetate salt.
6. The method of claim 1 , wherein the peptide is conjugated to keyhole limpet haemocyanin (KLH) or mannan.
7. The method of claim 1 , wherein the effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO: 9 or a peptide consisting of the amino acid sequence of SEQ ID NO: 9 in the form of a pharmaceutically acceptable salt is administered in the form of a composition.
8. The method of claim 7 , wherein the composition further comprises an adjuvant.
9. The method of claim 8 , wherein said adjuvant is selected from the group consisting of imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, interferon-alpha, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactid co-glycolid) (PLG) and virosomes.
10. The method of claim 2 , wherein the effective amount of the fusion protein is administered in the form of a composition.
11. The method of claim 10 , wherein the composition further comprises an adjuvant.
12. The method of claim 11 , wherein said adjuvant is selected from the group consisting of imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, interferon-alpha, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactid co-glycolid) (PLG) and virosomes.